Norovirus Genogroup II genotype 17 Major Capsid Protein (VP1) (GII.17 VP1)

The Norovirus Genogroup II genotype 17 (GII.17) Major Capsid Protein (VP1) is the primary structural component of the GII.17 norovirus, which emerged in 2014 (specifically the 'Kawasaki 2014' strain) as a major cause of epidemic gastroenteritis, particularly in Asia [Source: NCBI, PMID: 26233405]. The protein is organized into two main domains: the conserved Shell (S) domain that forms the internal icosahedral scaffold, and the Protruding (P) domain that extends outward from the viral surface [Source: PubMed, PMID: 26463162]. The P domain is further divided into P1 and P2 subdomains, with P2 being the most surface-exposed and variable region, housing the critical binding sites for host Histo-Blood Group Antigens (HBGAs) [Source: UniProt, A0A0A7D810]. As the principal target for neutralizing antibodies, VP1 is the central focus for norovirus vaccine development, often utilized in the form of Virus-Like Particles (VLPs) to mimic the viral structure without being infectious. Therapeutic strategies primarily aim to elicit antibodies that block the interaction between the VP1 P2 subdomain and host receptors, thereby inhibiting viral attachment and entry. Given the protein's propensity for rapid evolution, it remains a key subject of epidemiological surveillance to ensure that emerging 'escape mutants' are accounted for in next-generation multivalent vaccines [Source: HilleVax, Vaxart].

Other names

GII.17 Capsid ProteinVP1 Protein (GII.17)Norovirus GII.17 Major Capsid ProteinKawasaki 2014 strain VP1Major Capsid Protein VP1

Vaccine antigens (typically Virus-Like Particles or viral vectors) induce the production of neutralizing antibodies that target the P2 subdomain of the VP1 protein, effectively blocking the virus's ability to bind to host Histo-Blood Group Antigens (HBGAs) and preventing infection [Source: PubMed, PMID: 28943513].